61186372HNC3001 A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

by Mary Beth Wilwerding | Sep 3, 2026

EA3231 A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer with BRAF V600Em

by Mary Beth Wilwerding | Aug 19, 2026

EA3191 A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab after Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features

by Mary Beth Wilwerding | Aug 19, 2026

HN011 A Randomized Phase II Study of Nivolumab Versus Nivolumab and Relatlimab as Maintenance Treatment After First-Line Treatment with Platinum-Gemcitabine- Nivolumab for Patients with Epstein- Barr Virus-Associated Recurrent/Metastatic Nasopharyngeal Carcinoma

by Mary Beth Wilwerding | Aug 19, 2026

A092105 Randomized Phase 2 Study of Nivolumab and Ipilimumab with or without Cabozantinib in Patients with Advanced Nasopharyngeal Carcinoma That Have Progressed After Platinum Treatment with Immunotherapy

by Mary Beth Wilwerding | Aug 19, 2026